Literature DB >> 23207069

Genetically modified VSV(NJ) vector is capable of accommodating a large foreign gene insert and allows high level gene expression.

Hwa-Yong An1, Gyoung Nyoun Kim, Kunyu Wu, C Yong Kang.   

Abstract

It is desirable to develop a RNA virus vector capable of accommodating large foreign genes for high level gene expression. Vesicular stomatitis virus (VSV) has been used as a gene expression vector, especially Indiana serotype (VSV(Ind)), but less with New Jersey serotype (VSV(NJ)). Here, we report constructions of genetically modified rVSV(NJ) vector carrying various lengths of human hepatitis C virus (HCV) non-structural (NS) protein genes, level of inserted gene expression and characterization of rVSV(NJ). We modified the M gene of VSV(NJ) by changing methionine to arginine at positions 48 and 51 (rVSV(NJ)-M) (Kim and Kang, 2007) for construction of rVSV(NJ) with various lengths of HCV non-structural genes. The NS polyprotein genes of HCV were inserted between the G and L genes of the rVSV(NJ)-M vector, and recombinant VSV(NJ)-M viruses with HCV gene inserts were recovered by the reverse genetics. The recombinant VSV(NJ)-M vector with the HCV NS genes express high levels of all different forms of the NS proteins. The electron microscopic examination showed that lengths of recombinant VSV(NJ)-M without gene of interests, VSV(NJ)-M with a gene of HCV NS3 and NS4A (VSV(NJ)-M-NS3/4A), VSV(NJ)-M with a gene of HCV NS4AB plus NS5AB (VSV(NJ)-M-NS4AB/5AB), and VSV(NJ)-M carrying a gene of HCV NS3, NS4AB, and NS5AB (VSV(NJ)-M-NS3/4AB/5AB) were 172±10.5 nm, 201±12.5 nm, 226±12.9 nm, and 247±18.2 nm, respectively. The lengths of recombinant VSVs increased approximately 10nm by insertion of 1kb of foreign genes. The diameter of these recombinant viruses also increased slightly by longer HCV gene inserts. Our results showed that the recombinant VSV(NJ)-M vector can accommodate as much as 6000 bases of the foreign gene. We compared the magnitude of the IFN induction in mouse fibroblast L(Y) cells infected with rVSV(NJ) wild type and rVSV(NJ) M mutant viruses and show that the rVSV(NJ) M mutant virus infection induced a higher level of the IFN-β compare to the wild type virus. In addition, we showed that the NS protein expression level in IFN-incompetent cells (Mouse-L) infected with rVSV(NJ)-M viruses was higher than in IFN-competent L(Y) cells. In addition, we confirmed that HCV NS protein genes were expressed and properly processed. We also confirmed that NS3 protein expressed from the rVSV(NJ)-M cleaves NS polyprotein at junctions and that NS4A plays an important role as a co-factor for NS3 protease to cleave at the NS4B/5A site and at the NS5A/5B site.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207069     DOI: 10.1016/j.virusres.2012.11.007

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  13 in total

Review 1.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

2.  Generation of Recombinant Viral Hemorrhagic Septicemia Virus (rVHSV) Expressing Two Foreign Proteins and Effect of Lengthened Viral Genome on Viral Growth and In Vivo Virulence.

Authors:  Min Sun Kim; Su Jin Lee; Dong Soo Kim; Ki Hong Kim
Journal:  Mol Biotechnol       Date:  2016-04       Impact factor: 2.695

3.  Creation of matrix protein gene variants of two serotypes of vesicular stomatitis virus as prime-boost vaccine vectors.

Authors:  Gyoung Nyoun Kim; Kunyu Wu; Jiho Patrick Hong; Zain Awamleh; C Yong Kang
Journal:  J Virol       Date:  2015-04-08       Impact factor: 5.103

4.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Authors:  Samantha Burton; Lori M Spicer; Tysheena P Charles; Sailaja Gangadhara; Pradeep B J Reddy; Tiffany M Styles; Vijayakumar Velu; Sudhir Pai Kasturi; Traci Legere; Eric Hunter; Bali Pulendran; Rama Amara; Peter Hraber; Cynthia A Derdeyn
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

5.  Vaccine induction of antibodies and tissue-resident CD8+ T cells enhances protection against mucosal SHIV-infection in young macaques.

Authors:  Caroline Petitdemange; Sudhir Pai Kasturi; Pamela A Kozlowski; Rafiq Nabi; Clare F Quarnstrom; Pradeep Babu Jagadeesh Reddy; Cynthia A Derdeyn; Lori M Spicer; Parin Patel; Traci Legere; Yevgeniy O Kovalenkov; Celia C Labranche; François Villinger; Mark Tomai; John Vasilakos; Barton Haynes; C Yong Kang; James S Gibbs; Jonathan W Yewdell; Dan Barouch; Jens Wrammert; David Montefiori; Eric Hunter; Rama R Amara; David Masopust; Bali Pulendran
Journal:  JCI Insight       Date:  2019-02-21

6.  Evolution of genome size and complexity in the rhabdoviridae.

Authors:  Peter J Walker; Cadhla Firth; Steven G Widen; Kim R Blasdell; Hilda Guzman; Thomas G Wood; Prasad N Paradkar; Edward C Holmes; Robert B Tesh; Nikos Vasilakis
Journal:  PLoS Pathog       Date:  2015-02-13       Impact factor: 6.823

Review 7.  New frontiers in oncolytic viruses: optimizing and selecting for virus strains with improved efficacy.

Authors:  Kenneth Lundstrom
Journal:  Biologics       Date:  2018-02-09

8.  Immunogenicity in African Green Monkeys of M Protein Mutant Vesicular Stomatitis Virus Vectors and Contribution of Vector-Encoded Flagellin.

Authors:  Marlena M Westcott; Jason Smedberg; Matthew J Jorgensen; Shelby Puckett; Douglas S Lyles
Journal:  Vaccines (Basel)       Date:  2018-03-19

9.  A recombinant novirhabdovirus presenting at the surface the E Glycoprotein from West Nile Virus (WNV) is immunogenic and provides partial protection against lethal WNV challenge in BALB/c mice.

Authors:  Angella Nzonza; Sylvie Lecollinet; Sophie Chat; Steeve Lowenski; Emilie Mérour; Stéphane Biacchesi; Michel Brémont
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

Review 10.  Replicon RNA Viral Vectors as Vaccines.

Authors:  Kenneth Lundstrom
Journal:  Vaccines (Basel)       Date:  2016-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.